MS & Immune Disorders
News
Gray Matter Atrophy in Multiple Sclerosis May Occur Independently of Clinically Effective Treatment
Friday, December 21, 2018—Once thought to be a disease only of white matter, the myelin sheath of oligoglia, it is now accepted that multiple sclerosis (MS) affects nerve cells themselves, the gray mat…
New Drug Application Submitted for Therapy for Multiple Sclerosis
Tuesday, December 18, 2018—A New Drug Application (NDA) has been submitted to the US Food and Drug Administration (FDA) for diroximel fumarate (BIIB098/Vumerity; Alkermes PLC, Waltham, MA), a novel oral…
FDA Approves Amifampridine for Lambert-Eaton Myasthenic Syndrome
Monday, December 03, 2018—The FDA has approved amifampridine (Firdapse, Catalyst Pharmaceuticals, Coral Gables, FL) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. This…
Warning Issued for Possible Stroke Risk When Starting Alemtuzumab
Friday, November 30, 2018—The Food and Drug Administration (FDA) has issued a warning about possible risk of stroke and neurovascular injury for patients starting treatment with alemtuzumab (Lemtrada, …
Biases in Dementia Screening Tools
Wednesday, November 28, 2018—Brief cognitive tests are useful screening tools for dementia in the primary care setting; however, a study published in the journal Neurology Clinical Practice show…
Possible Therapy for Polio-Like Illness Is Not Effective
Tuesday, November 13, 2018—In new research on a potential treatment for acute flaccid myelitis, the antidepressant fluoxetine showed no efficacy. The study, published in the November 9, 2018 online issu…
New Data Available on Risk of Relapse During Pregnancy for Women With Multiple Sclerosis
Tuesday, October 23, 2018—Multiple sclerosis (MS) most often affects women of childbearing age, making family planning and management of the disease before, during, and after pregnancy a primary concer…
Evobrutinib—A First-in-Class Drug—Shows Efficacy in Phase 2 Clinical Trials
Friday, October 12, 2018—October 12, 2018 -- At the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, German October 10-12, results from a double-blind pl…
